medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 2

<< Back Next >>

Med Int Mex 2020; 36 (2)

Heart as an endocrine organ

García-Arias MR, Gómez-Acosta SA, Medina-Galindo J, Alavez-Torres E, Cedillo-Urbina MR, Azuara-Negrete ND, García-Garcilazo LA, Gonzaga-López TI

Language: Spanish
References: 34
Page: 199-211
PDF size: 295.51 Kb.


ABSTRACT

In the 1960s, hence the concept of the heart as an endocrine organ after the work carried out by Braunwald, about the function of norepinephrine. Afterwards, through the study of the physiology of atrial and ventricular cardiomyocytes it was identified a family of hormones with paracrine function known as natriuretic peptides; molecules with different functions related with a homeostasis effect on blood volume, cardiac output, serum concentrations of sodium and total body water. These studies were the guideline to identify new molecules related with the contractile function of the heart. Example: endothelin’s family, adrenomoduline and, recently, the function of neprilisine and cromogranine. In 2003, it was identified the relationship of these peptides to lipolyisis and thus, to the serum concentrations of triglycerides, cholesterol, glucose and peripheral insulin sensitivity. Nowadays, the study of these molecules isn’t limited only in cardiovascular physiology, it has been extended to other areas of medicine; introducing new knowledge in clinics, new diagnostic tools, and therapeutic targets related to cardiovascular diseases. This review emphasizes the endocrine function of heart, leading apart the traditional concept of heart as a pump, and taking to a well-rounded and integral concept of it as an endocrine organ.


REFERENCES

  1. Ogawa T, de Bold AJ. The heart as an endocrine organ. Endocr Connect 1983;(13):1-14. doi: 10.1530/EC-14-0012. Print 2014.

  2. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Jens P. Natriuretic peptides in cardiometabolic regulation and disease. Nat Publ Gr [Internet]. 2014;(Table 1). Available from: http://dx.doi.org/10.1038/nrcardio.2014.64.

  3. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B. Atrial secretion of B-type natriuretic peptide. Eur Heart J 2006 Jul;27(14):1648-50. DOI: 10.1093/eurheartj/ehl109.

  4. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. 2009;341–66.

  5. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure : from molecular basis to treatment. Handb Exp Pharmacol 2016;57-77. DOI: https://dx.doi.org/10.1007% 2F978-3-540-68964-5_15.

  6. Lee NS, Daniels LB. Pathophysiology current understanding of the compensatory actions of cardiac natriuretic peptides in cardiac failure : a clinical perspective a clinical perspective on CNPs in cardiac failure. Card Fail Rev 2016;14-9. DOI: https://dx.doi.org/10.15420%2Fcfr.2016%3A4%3A2.

  7. Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, Galitzky J. Involvement of a cGMP-dependent pathway in the natriuretic in human adipocytes. 2003;278(49):48617-26.

  8. Stanford KI, Tseng Y, Goodyear LJ, Stanford KI, Middelbeek RJW, Townsend KL, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest 2013;123(1):215–23. doi: 10.1172/JCI62308.

  9. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;660-7. https://doi.org/10.1161/01. HYP.0000179575.13739.72.

  10. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Associate editor: Eric l. Barker 2016;95499.

  11. Valdez NF. Endotelina-1: vasoconstrictor intrínseco del endotelio vascular endothelin-1: intrinsic vasoconstrictor vascular endothelial Abstract A endotelina-1: endotelial vascular vasoconstritor intrínseco. Revista Med 2013;21(2):64-78.

  12. Plante M. S Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003;(April 2015). https://doi. org/10.1139/y03-032.

  13. Lipp MB, Crespo HR, Ortega Martínez J, Sotres-Vega A, Enrique M, Lipp B. Sistema endotelina. Revista del Instituto Nacional de Enfermedades Respiratorias. Segunda época. 2005;18.

  14. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. 2001;21(3):999-1006.

  15. Montezano AC, Touyz RM, Webb RC, Carvalho MHC. Endothelin, sex and hypertension. 2008;97:85-97. DOI: 10.1042/CS20070169.

  16. Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol [Internet] 35(2):125- 36. Available from: http://dx.doi.org/10.1016/j.semnephrol. 2015.02.002.

  17. Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014 Jun 18;2014(2):62-78. doi: 10.5339/gcsp.2014.29.

  18. Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J 1974;137:477-88. DOI: 10.1042/bj1370477.

  19. Moss S, Subramanian V, Acharya KR. High resolution crystal structure of substrate-free human neprilysin. J Struct Biol [Internet] 2018;204(1):19-25. Available from: https://doi. org/10.1016/j.jsb.2018.06.004.

  20. Bayés-Genís A, Barallat J, Galán A, De Antonio M, Domingo M, Zamora E, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 2015;65(7):657-65. doi: 10.1016/j.jacc.2014.11.048.

  21. Vodovar N, Lassus J, Boukef R, Manivet P, Cohen-solal A, Mebazaa A. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail. 2015 Aug;3(8):629-36. doi: 10.1016/j.jchf.2015.03.011.

  22. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med [Internet] 2014;371(11):993-1004. Available from: http://www.nejm. org/doi/10.1056/NEJMoa1409077.

  23. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, et al. Myocardial production of chromogranin A in human heart : a new regulatory peptide of cardiac function. Eur Heart J 2007;39(0). DOI: 10.1093/eurheartj/ehm022.

  24. Semenov AG, Katrukha AG. Different susceptibility of B-type natriuretic Peptide (BNP) and BNP precursor (proBNP) to cleavage by neprilysin: The n-terminal part does matter. Clin Chem 2016;62(4):617-22. doi: 10.1373/ clinchem.2016.254524.

  25. Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrotkowska E, et al. State of the art paper. Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 2016;12:1-9. https://doi.org/10.5114/aoms.2016.57577.

  26. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, et al. Chromogranin A in heart failure A novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002;967-74. https://doi.org/10.1053/euhj.2001.2977.

  27. Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 2003 Jan;114(1):25-30. DOI: 10.1016/s0002-9343(02)01425-0.

  28. Glattard E, Angelone T, Strub J, Corti A, Aunis D. Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 2006;273:3311-21. DOI: 10.1111/j.1742- 4658.2006.05334.x.

  29. Troger J, Theurl M, Kirchmair R, Pasqua T, Tota B, Angelone T, et al. Progress in neurobiology granin-derived peptides. Prog Neurobiol [Internet] 2017;154:37-61. Available from: http://dx.doi.org/10.1016/j.pneurobio.2017.04.003.

  30. Sanchez V, et al. Glycogenolytic effect of pancreastatin in the rat. 1990;I(1):87-91.

  31. Wang X, Xu S, Liang Y, Zhu D, Mi L, Wang G, et al. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 2011;16(February): 372-7. doi: 10.3109/1354750X.2011.578260.

  32. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;1509-17. doi: 10.1056/NEJMoa0810780.

  33. Schlueter N, Sterke A De, Willmes DM, Spranger J, Jordan J, Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol Ther 2014;144:12-27. doi: 10.1016/j.pharmthera. 2014.04.007.

  34. Li W, Abdul Y, Ward R, Ergul A, Norwood C, Affairs V, et al. Endothelin and diabetic complications: a brain-centric view. Physiol Res 2018;67. DOI: 10.33549/physiolres.933833.




2020     |     www.medigraphic.com